Entrada Therapeutics (TRDA) Operating Expenses (2020 - 2026)

Entrada Therapeutics' Operating Expenses history runs 7 years deep, the most recent figure standing at $43.2 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 1.96% year-over-year to $43.2 million in Q1 2026; TTM through Mar 2026 was $184.1 million, a 9.54% increase from a year earlier, with the FY2025 full-year figure at $183.3 million, up 11.94% from the prior year.
• Operating Expenses fell to $43.2 million in Q1 2026 per TRDA's latest filing, from $43.5 million in the prior quarter.
• Across five years, Operating Expenses topped out at $48.8 million in Q2 2025 and bottomed at $22.2 million in Q1 2022.
• The 5-year median for Operating Expenses is $38.0 million (2024), against an average of $36.5 million.
• Across the five-year window, Operating Expenses jumped 163.92% in 2022 and gained 0.56% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $25.6 million in 2022, then jumped by 44.43% to $36.9 million in 2023, then advanced by 17.11% to $43.3 million in 2024, then grew by 0.56% to $43.5 million in 2025, then declined by 0.76% to $43.2 million in 2026.
• Per Business Quant, the three latest TRDA Operating Expenses figures stand at $43.2 million (Q1 2026), $43.5 million (Q4 2025), and $48.7 million (Q3 2025).